Publication:
Appraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis

dc.contributor.authorÖZDOĞAN, OSMAN CAVİT
dc.contributor.authorsYegin, Ender Gunes; Durusoy, Salih S.; Ozdemir, Filiz Ture; Kombak, Erdem F.; Ataizi-Celikel, Cigdem; Ozdogan, Osman C.
dc.date.accessioned2022-03-14T09:18:02Z
dc.date.accessioned2026-01-10T20:26:09Z
dc.date.available2022-03-14T09:18:02Z
dc.date.issued2019-11
dc.description.abstractIntroduction and objectives: A crucial issue when appraising the performance of non-invasive markers is the limitations of the reference standard they are compared to. Digital image analysis (DIA) was suggested as a reproducible approach expressing fibrosis numerically as a proportionate area (PA) (%). We aimed to evaluate ELF test with direct reference to PA (%), thereby explore the improvement in accuracy to discriminate significant fibrosis which may actually have been underestimated by categorical pathological staging. Materials and methods: PA (%) data were obtained by DIA of trichrome-stained liver biopsies of 52 chronic hepatitis patients. Paired serum samples of patients and additional 36 controls were performed to measure ELF test. Diagnostic performance characteristics of ELF test was derived in predicting significant fibrosis in the patient cohort, and also, in distinguishing healthy controls from patients with significant fibrosis. Results: We found an AUROC value of 0.73 for ELF to predict significant fibrosis as assessed by DIA and a lower AUROC value of 0.66 when assessed by conventional pathology. Importantly, ELF test provided considerably high diagnostic accuracy to discriminate healthy controls from patients with significant fibrosis defined by Ishak F >= 2 and TPA >= 5% (AUROCs 0.93 and 0.94, respectively) with optimal ELF cut-off point of 8.4 for both. Conclusions: Digital quantification could represent a better reference standard than conventional pathology allowing a better discriminatory capability for ELF test. ELF test provided high diagnostic accuracy to discriminate healthy controls from patients with significant fibrosis suggesting a role as a screening strategy in the community setting. (C) 2019 Fundacion Clinica Medica Sur, A.C. Published by Elsevier Espana, S.L.U.
dc.identifier.doi10.1016/j.aohep.2019.06.015
dc.identifier.issn1665-2681
dc.identifier.pubmed31558418
dc.identifier.urihttps://hdl.handle.net/11424/242934
dc.identifier.wosWOS:000496943100010
dc.language.isoeng
dc.publisherELSEVIER ESPANA
dc.relation.ispartofANNALS OF HEPATOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectEnhanced liver fibrosis test
dc.subjectDigital image analysis
dc.subjectPathological stages
dc.subjectCOLLAGEN PROPORTIONATE AREA
dc.subjectSERUM MARKER PANELS
dc.subjectCHRONIC HEPATITIS-C
dc.subjectIMAGE-ANALYSIS
dc.subjectTRANSIENT ELASTOGRAPHY
dc.subjectCLINICAL-OUTCOMES
dc.subjectCIRRHOSIS
dc.subjectSCORE
dc.subjectPROGRESSION
dc.subjectINTEROBSERVER
dc.titleAppraising diagnostic performance of ELF test by pathological staging and digital quantification of liver fibrosis
dc.typearticle
dspace.entity.typePublication
oaire.citation.endPage840
oaire.citation.issue6
oaire.citation.startPage833
oaire.citation.titleANNALS OF HEPATOLOGY
oaire.citation.volume18

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
file.pdf
Size:
1.15 MB
Format:
Adobe Portable Document Format